Illumina says Verinata reimbursements exceeding expectations At the UBS Healthcare Conference earlier today, Illumina (ILMN) CFO Marc Stapley said adoption for the company's Verinata prenatal test has met expectations, while reimbursement for the test has exceeded expectations, adding that its relationship with PerkinElmer (PKI) has allowed the company to obtain significant coverage decisions. In afternoon trading, shares of Illumina are up $1.48, or 2.06%, to $73.48.
PerkinElmer has a conference call hosted by JPMorgan JPMorgan Analyst Peterson will host a conference call with CEO Rob Friel and CFO Andy Wilson on May 16 at 11 am.
Subscribe for More Information